cannabis indica

Epilepsia — Síndrome de Dravet

termo de indexação original: Epilepsy - Dravet Syndrome

O acervo do Cannabis Indica reúne 143 estudos científicos que tocam a condição Epilepsia — Síndrome de Dravet, publicados entre 1893 e 2024. Pela leitura automatizada, 120 (84%) foram classificados como favoráveis, 15 (10%) como inconclusivos e 8 (6%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (73 estudos), seguido de ensaio clínico (23). Os compostos mais presentes são CBD Farmacêutico, Tetraidrocanabinol (THC) e THC Farmacêutico. Aparece com frequência ao lado de Epilepsia, Epilepsia — Lennox-Gastaut e Dor.

Estudos indexados
143
Período coberto
1893–2024
Favoráveis
120 · 84%
Inconclusivos
15 · 10%
Desfavoráveis
8 · 6%
Termo original
Epilepsy - Dravet Syndrome

O acervo em números

Tipo de estudo

Metanálise73
Ensaio Clínico23
Metanálise Clínica19
Estudo em Animais11
Ensaio Clínico Duplo-Cego9
Estudo Laboratorial8

Direção do resultado

Favorável120
Inconclusivo15
Desfavorável8

Por década

1890s1
1940s1
1980s1
2010s51
2020s89

143 estudos

Filtrar e buscar no acervo →
  1. 2024

    Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials

    FavorávelMetanálise ClínicaEpilepsia
  2. 2024

    Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials

    InconclusivoMetanálise ClínicaEpilepsia
  3. 2024

    The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials

    FavorávelMetanálise ClínicaEpilepsiaCBD Farmacêutico
  4. 2023

    A Rare Case of Cannabinoid Hyperemesis Syndrome Secondary to Cannabidiol for Refractory Epilepsy

    DesfavorávelMetanáliseEfeitos Adversos da CannabisEpilepsiaNáusea e Vômito+3
  5. 2023

    Biotechnological Fungal Platforms for the Production of Biosynthetic Cannabinoids

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoTetraidrocanabinol (THC)THC Farmacêutico+25
  6. 2023

    Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study

    FavorávelEnsaio Clínico Duplo-CegoDorCâncerDor — CrônicaTHC FarmacêuticoTHC:CBD Farmacêutico+8
  7. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  8. 2023

    Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  9. 2023

    Could cannabinoids provide a new hope for ovarian cancer patients?

  10. 2023

    Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance

    FavorávelMetanáliseCâncerInflamaçãoAnsiedadeCanabigerol (CBG)Canabinol (CBN)+20
  11. 2023

    Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids

    InconclusivoEstudo LaboratorialCâncerInflamaçãoEpilepsiaTetraidrocanabinol (THC)CBD Farmacêutico+3
  12. 2023

    Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    FavorávelMetanáliseEpilepsiaQualidade de Vida
  13. 2023

    Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends

    FavorávelMetanáliseDorCâncerDor — CrônicaTHC FarmacêuticoCBD Farmacêutico+16
  14. 2023

    Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

    FavorávelMetanálise ClínicaEpilepsiaCBD Farmacêutico
  15. 2023

    Use of non-medical cannabis in epilepsy: A scoping review

  16. 2022

    A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication

    FavorávelMetanáliseEpilepsiaDisfunção CognitivaCBD Farmacêutico
  17. 2022

    A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

    FavorávelMetanáliseDorCâncerAnsiedadeAnandamida (AEA)Tetraidrocanabinol (THC)+25
  18. 2022

    Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial

    InconclusivoEnsaio Clínico Duplo-CegoEpilepsiaEpilepsia — Lennox-Gastaut
  19. 2022

    Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy

  20. 2022

    Cannabidiol in canine epilepsy

    InconclusivoMetanáliseDorCâncerInflamaçãoÁcido Canabidiólico (CBD-a)+7
  21. 2022

    Cannabinoids in rheumatology: Friend, foe or a bystander?

  22. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

  23. 2022

    Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis

  24. 2022

    Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

    FavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+28
  25. 2022

    Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review

    FavorávelMetanáliseAnsiedadeEpilepsiaObesidadeTetraidrocanabinol (THC)+5
  26. 2022

    Effects of short-term environmental stresses on the onset of cannabinoid production in young immature flowers of industrial hemp (Cannabis sativa L.)

    FavorávelEstudo LaboratorialCâncerEpilepsiaDoença de ParkinsonCanabigerol (CBG)Canabinol (CBN)+4
  27. 2022

    Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

    FavorávelMetanálise ClínicaEpilepsia
  28. 2022

    Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap

  29. 2022

    Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story?

  30. 2022

    Epilepsy and cannabis: so near, yet so far

    DesfavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  31. 2022

    Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  32. 2022

    Movement Disorders Secondary to Novel Antiseizure Medications in Pediatric Populations: A Systematic Review and Meta-analysis of Risk

    InconclusivoMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  33. 2022

    Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome

    FavorávelEstudo em AnimaisEpilepsiaÁcido Canabigerólico (CBG-a)
  34. 2022

    Persistent Diarrhea and Eosinophilic Esophagitis Resulting From Chronic Cannabidiol Usage for Refractory Epilepsy

    DesfavorávelMetanáliseDorEpilepsiaDII — Doença Inflamatória Intestinal+3
  35. 2022

    Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know

  36. 2022

    Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants

  37. 2022

    TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids

  38. 2022

    Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  39. 2021

    Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial

    FavorávelEnsaio ClínicoEpilepsia
  40. 2021

    An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models

  41. 2021

    Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome

    FavorávelEstudo em AnimaisEpilepsiaCanabicromeno (CBC)Ácido Canabicromênico (CBC-a)
  42. 2021

    Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial

  43. 2021

    Cannabidiol and mental health: possibilities, uncertainties, and controversies for addiction treatment

    InconclusivoMetanáliseDependência QuímicaAnsiedadeDepressão+10
  44. 2021

    Cannabidiol and Neurodevelopmental Disorders in Children

  45. 2021

    Cannabidiol and Sodium Channel Pharmacology: General Overview, Mechanism, and Clinical Implications

    FavorávelMetanáliseEpilepsia
  46. 2021

    Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  47. 2021

    Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  48. 2021

    Cannabidiol in the Treatment of Epilepsy

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  49. 2021

    Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review

    DesfavorávelMetanáliseDepressãoEpilepsiaDependência — OpioidesCBD Farmacêutico+3
  50. 2021

    Cannabidiol treatment of severe refractory epilepsy in children and young adults

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  51. 2021

    Cannabidiol: pharmacology and therapeutic targets

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+4
  52. 2021

    Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

    FavorávelEstudo em AnimaisEpilepsiaÁcido Canabigerólico (CBG-a)
  53. 2021

    Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautAutismo
  54. 2021

    Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome

    FavorávelEstudo em AnimaisEpilepsia
  55. 2021

    Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

  56. 2021

    Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

    DesfavorávelEstudo LaboratorialEpilepsiaEpilepsia — Lennox-GastautHepatiteCBD Farmacêutico+1
  57. 2021

    Dravet syndrome

    FavorávelMetanáliseEpilepsia
  58. 2021

    Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  59. 2021

    Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

  60. 2021

    Efficacy and safety of paediatric medicinal cannabis use: A scoping review

    DesfavorávelMetanáliseDorCâncerEpilepsiaTHC FarmacêuticoCBD Farmacêutico+6
  61. 2021

    Epileptic Phenotype and Cannabidiol Efficacy in a Williams–Beuren Syndrome Patient With Atypical Deletion: A Case Report

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  62. 2021

    Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-Gastaut
  63. 2021

    Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study

    FavorávelEnsaio ClínicoDorAnsiedadeDor — CrônicaCBD Farmacêutico+3
  64. 2021

    Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  65. 2021

    Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  66. 2021

    New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  67. 2021

    Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer

    FavorávelMetanáliseDorCâncerDor — Crônica+7
  68. 2021

    Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

    FavorávelEstudo em AnimaisEpilepsia
  69. 2021

    Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  70. 2021

    Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  71. 2021

    Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder

    InconclusivoMetanálise ClínicaEpilepsiaEpilepsia — Lennox-Gastaut
  72. 2021

    Two-center experience of cannabidiol use in adults with Dravet syndrome

  73. 2020

    A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  74. 2020

    A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

  75. 2020

    A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  76. 2020

    Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety

    FavorávelMetanálise ClínicaEpilepsia
  77. 2020

    Cannabidiol (CBD)

    FavorávelMetanáliseInflamaçãoAnsiedadeEpilepsia+4
  78. 2020

    Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  79. 2020

    Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  80. 2020

    Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  81. 2020

    Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials

    FavorávelMetanálise ClínicaEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  82. 2020

    Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  83. 2020

    Drug-Drug Interactions Between Cannabidiol and Lithium

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautAutismo+1
  84. 2020

    Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis

    FavorávelMetanáliseEpilepsia
  85. 2020

    Effect of Cannabinoids on Electroencephalography of a Child with Lennox-Gastaut Syndrome

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  86. 2020

    Interactions between cannabidiol and Δ 9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome

    FavorávelEstudo em AnimaisEpilepsia
  87. 2020

    Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  88. 2020

    Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model

  89. 2020

    Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  90. 2019

    A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  91. 2019

    A systematic review of cannabidiol dosing in clinical populations

    FavorávelMetanálise ClínicaDorDependência — CannabisAnsiedade+14
  92. 2019

    Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

    DesfavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  93. 2019

    Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases

    FavorávelMetanáliseInflamaçãoDepressãoEpilepsia+14
  94. 2019

    Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome

    InconclusivoMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  95. 2019

    Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  96. 2019

    Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  97. 2019

    Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  98. 2019

    Cannabinoid therapy in epilepsy

    InconclusivoMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  99. 2019

    Cannabis and Epilepsy

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  100. 2019

    Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  101. 2019

    Cannabis-based products for pediatric epilepsy: A systematic review

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  102. 2019

    Cannabis-based treatments as an alternative remedy for epilepsy

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  103. 2019

    Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

    FavorávelEstudo em AnimaisEpilepsiaEpilepsia — Lennox-Gastaut
  104. 2019

    Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy

    InconclusivoMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  105. 2019

    Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study

    FavorávelEnsaio ClínicoEpilepsiaCanabicromeno (CBC)
  106. 2019

    Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings

    FavorávelMetanáliseAnsiedadeEpilepsiaPsicose+3
  107. 2019

    Efficacy of cannabinoids in paediatric epilepsy

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  108. 2019

    Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

    FavorávelEnsaio ClínicoEpilepsiaPerda de ApetiteDiarreiaCBD Farmacêutico+1
  109. 2019

    Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautDiarreiaCBD Farmacêutico
  110. 2019

    Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

    InconclusivoEnsaio ClínicoEfeitos Adversos da CannabisEpilepsiaEpilepsia — Lennox-Gastaut
  111. 2019

    Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome

    FavorávelEstudo em AnimaisEpilepsiaÁcido Canabidiólico (CBD-a)
  112. 2019

    Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  113. 2019

    Plants come to mind: phytocannabinoids, endocannabinoids and the control of seizures

    FavorávelMetanáliseEpilepsiaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  114. 2019

    Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-Gastaut
  115. 2019

    Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  116. 2019

    The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-Gastaut
  117. 2019

    Treatment of Seizures Associated with Lennox-Gastaut and Dravet Syndromes: A Focus on Cannabidiol Oral Solution

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  118. 2018

    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

  119. 2018

    A prospective open-label trial of a CBD/THC cannabis oil in Dravet Syndrome.

    FavorávelEnsaio ClínicoEpilepsiaQualidade de VidaTetraidrocanabinol (THC)
  120. 2018

    Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial

  121. 2018

    Cannabidiol for drug-resistant seizures in the Dravet syndrome

    FavorávelEnsaio ClínicoEpilepsiaNáusea e VômitoAnorexia (perda de apetite)+1
  122. 2018

    Cannabis for paediatric epilepsy: challenges and conundrums

    FavorávelMetanáliseEpilepsia
  123. 2018

    Cannabis for the Treatment of Epilepsy: an Update

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  124. 2018

    Cannabis Therapeutics and the Future of Neurology

  125. 2018

    Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  126. 2018

    Investigating the Therapeutic Mechanism of Cannabidiol in a Human Induced Pluripotent Stem Cell (iPSC)-Based Model of Dravet Syndrome

    FavorávelEstudo LaboratorialEpilepsia
  127. 2018

    Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  128. 2018

    Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaNáusea e VômitoPerda de Apetite
  129. 2017

    Cannabidiol Attenuates Seizures And Social Deficits In A Mouse Model Of Dravet Syndrome

    FavorávelEstudo em AnimaisEpilepsiaAutismo
  130. 2017

    Cannabinoids in treatment-resistant epilepsy: A review.

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  131. 2017

    Neurological Aspects Of Medical Use Of Cannabidiol

    FavorávelMetanáliseEpilepsiaDisfunção CognitivaEsclerose Múltipla+4
  132. 2017

    Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

    FavorávelEnsaio Clínico Duplo-CegoEpilepsiaNáusea e VômitoDiarreiaCBD Farmacêutico
  133. 2016

    A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs)

  134. 2016

    Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.

    FavorávelEstudo LaboratorialEpilepsia
  135. 2016

    Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.

    FavorávelEstudo LaboratorialEpilepsia2-Araquidonoilglicerol (2-AG)Monoacilglicerol Lipase (MAGL)+1
  136. 2016

    Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers

  137. 2014

    Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

  138. 2014

    Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Initial Data From an Expanded Access Program.

    FavorávelEnsaio ClínicoEpilepsiaEpilepsia — Lennox-GastautCBD Farmacêutico
  139. 2014

    Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se.

    FavorávelEstudo em AnimaisEpilepsiaCanabigerol (CBG)
  140. 2013

    Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

    FavorávelMetanáliseEpilepsiaEpilepsia — Lennox-Gastaut
  141. 1981

    Hypnotic And Antiepileptic Effects Of Cannabidiol

    FavorávelMetanálise ClínicaEpilepsiaInsônia e Distúrbios do SonoEpilepsia — Lennox-Gastaut
  142. 1949

    Anti-epileptic Action of Marijuana-Active Subtances

  143. 1893

    Report of the Indian Hemp Drugs Commission, 1893-1894 (Volume 1)

Continue por aqui

Perguntas frequentes

Quantos estudos sobre epilepsia — síndrome de dravet estão indexados no acervo?
São 143 estudos, publicados entre 1893 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 73 · Ensaio Clínico: 23 · Metanálise Clínica: 19 · Estudo em Animais: 11 · Ensaio Clínico Duplo-Cego: 9 · Estudo Laboratorial: 8. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 120 favoráveis, 15 inconclusivos e 8 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Epilepsia — Síndrome de Dravet — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/epilepsia-sindrome-de-dravet/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Epilepsia — Síndrome de Dravet — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/epilepsia-sindrome-de-dravet/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.